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Abstract : A patient’s pain intensity rating alone is insufcient grounds for determining 
the pain medication and dosage to administer daily.  This study aimed to investigate 
whether a convenient assessment method could be developed that would reflect the 
effectiveness of an opioid analgesic on cancer patients’ pain management.  We inves-
tigated pain intensity （worst, least, average, current） and the effectiveness of the 
opioid rescue medication in terms of patient satisfaction.  This study used Spear-
man’s rank correlation coefficients to evaluate the relationships between patient 
satisfaction with rescue medication and both pain intensity and the medication’
s perceived effectiveness.  Data from 60 participants with a mean age of 60.5±
11.4 years （range: 31-79 years） were analyzed.  Thirty-eight （63.3%） participants 
were male, and 22 （36.7%） were female.  The correlations found between rescue 
medication satisfaction and both the worst numerical rating scale （NRS） rating （r
＝-0.15, P＝0.16） and the average NRS rating （r＝-0.13, P＝0.13） were not sta-
tistically signicant.  A signicant positive correlation was observed between rescue 
medication satisfaction and the medication’s perceived effectiveness （r＝0.79, P＜
0.0001）.  Patient satisfaction with their rescue medication can be routinely assessed 
without imposing a signicant burden on the patient.  A new assessment method 
incorporating rescue medication satisfaction and pain intensity measures could 
allow routine pain assessments to reect both pain intensity and the effectiveness 
of opioid analgesics.  This new assessment method is potentially preferable to self-
reported pain intensity and can identify patients for whom treatment is a priority.  
It also facilitates rapid dose adjustments and reduces the side effects of overdose 
due to unnecessary increases in opioid analgesics..
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Introduction
　Pain is the most frequent complication related to cancer.  Approximately 40％ of cancer 
patients experience moderate-to-severe pain at the time of diagnosis, which increases to 70％ 
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toward the end of life.  Cancer pain control is frequently suboptimal despite the availability 
of generic effective pain treatments.  Factors including the underreporting of pain by cancer 
patients, inadequate communication regarding pain between patients and medical staff, and 
inadequate assessment of pain by professionals are known to contribute to poor pain control1）. 
The development of new guidelines for treatment and the increased worldwide consumption 
of opioid analgesics is expected to reduce cancer patients’ levels of pain.  However, effective 
pain management has not been implemented, and knowledge concerning the evaluation and 
management of cancer pain by medical staff remains inadequate2）. 
　The effective treatment of cancer-related pain increases the efficacy of cancer treatment3）. 
Basing pain assessment on patient-reported outcomes （PROs）4） is considered to be best practice 
when assessing cancer-related pain management outcomes.  Numerous studies of such assessment 
methods have been conducted5, 6）, such as the 1993 European Organization for Research and 
Treatment of Cancer Quality of Life Questionnaire-Core Module 30 （EORTC QLQ-C30）7）.  In 
Japan, studies have been performed using the Japanese versions of the Brief Pain Inventory 
（BPI-J）8） and the European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire-Core Module 15-Palliative Care （EORTC QLQ-C15-PAL）9）. These measures have 
also been used to assess the effects of different pain intensity levels on patient pain management 
satisfaction and daily living10）. Both instruments comprise a lengthy series of questions, which, 
although suitable for patients participating in clinical trials or for those receiving outpatient 
treatment, could be burdensome for staff attempting to use them frequently in clinical settings.
　Pain management is complex for patients with cancer-related pain.  It requires a comprehensive 
evaluation of the potential causes （physical examinations, imaging scans, and blood tests） and the 
effects of the pain （impact on everyday life, patterns, intensity, location, history, type, aggravating or 
mitigating factors, and response to treatment）11, 12）. Moreover, methodologies differ in their details. 
For example, numerous rating scales are used to assess pain intensity alone, including the visual 
analog scale, the numerical rating scale （NRS）, and the faces pain scale.
　At the Showa University Hospital, pain intensity is continually assessed for most patients. 
However, a patient’s pain intensity rating alone is insufficient grounds for determining the pain 
medication and dosage to administer daily.  Therefore, in this study, we examined other factors 
that may be less adequately monitored.  Although including patient pain management satisfaction 
could potentially improve assessment utility, satisfaction with overall treatment for pain also 
reflects the effects of other factors, such as the efficacy of the patient’s overall cancer treatment. 
To address this issue, we examined patient satisfaction with an opioid analgesic that was taken as 
a rescue medication when the patient experienced severe pain.
　This study aimed to investigate whether a convenient assessment method could be developed 
that would reflect the effectiveness of an opioid analgesic for cancer patients’ pain management. 
To that end, this study examined whether patient satisfaction with their rescue medication was 
correlated with pain intensity and perceived medication effectiveness.  The reasons underlying 
high patient satisfaction levels were also evaluated, and data collected related to rescue 
medication selection were considered in relation to the findings.
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Methods
Participants and Procedure
　This was a cross-sectional study.  The sample population for the study consisted of cancer 
patients admitted to Showa University Hospital between April and November of 2019 who were 
assessed for cancer-related pain as part of the palliative care team’s interventions.  Participants 
who had been on an opioid analgesic for at least one week and had a pain assessment 
performed were selected for participation in the study.  Of this group, consenting patients 
aged 20-79 years old who had an Eastern Cooperative Oncology Group performance status 
（ECOG-PS） score of 3 or less were asked to complete a pain assessment survey questionnaire 
in conjunction with their regular pain assessments.  The surveys were completed at minimum 
intervals of six days; therefore, a specific patient could potentially complete multiple surveys.  The 
self-administered survey consisted of eight items.  Data for the first item （patient characteristics） 
were obtained from the patient’s electronic health record.  The remainder of the items were 
completed by the patient unless they were unable to do so.  In such cases, medical staff 
members were permitted to assist them.  Patients were excluded from the study if they were at 
risk for respiratory depression due to a head injury or enlarged brain tumor, or if the physician 
leading the research project determined them to be unfit to participate for any reason.
Survey Content
　The survey collected the following content using demographic variables, the NRS scores, and 
assessments of satisfaction:
　1． Participant characteristics : age, gender, type of cancer, whether they were receiving cancer 
treatment, ECOG-PS score, regularly prescribed opioid analgesic, opioid analgesic dosage, 
and opioid analgesic dosage form
　2．Most intense pain during the past 24 hours （worst NRS）
　3．Least intense pain during the past 24 hours （least NRS）
　4．Average pain intensity over the past 24 hours （average NRS）
　5．Pain intensity when completing the survey （current NRS）
　6．Effectiveness of the rescue medication
　7．Satisfaction with the rescue medication
　8．Reasons for the satisfaction rating
　The pain assessment survey questionnaire was developed based on the BPI-J, for which the validity 
and reliability have already been confirmed as sufficient. The BPI-J is frequently used in research to 
assess cancer-related pain.  For items 2-5, an 11-point NRS was used ranging from 0 （no pain） to 10 
（worst pain ever experienced）.  For item 6, an 11-point scale was used ranging from 0 （no effect） 
to 10 （extremely effective）.  For item 7, an 11-point scale was used, ranging from 0 （extremely 
dissatisfied） to 10 （extremely satisfied）.  Item 8 examined the reasons the patient was satisfied or 
dissatisfied with their rescue medication; multiple responses were possible: i） it is fast-acting; ii） it is 
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slow-acting; iii） it lasts a long time; iv） it lasts a short time; v） the side effects are bad; vi） it has 
no side effects; vii） it is convenient; viii） the preparation time is too long; ix） it does not have to 
be drunk; and x） other （a space was provided for patients to provide more details）.
　The study’s primary analyses examined how rescue medication satisfaction might correlate with 
pain intensity （worst and average NRS ratings） and with medication effectiveness.  Secondary 
analyses compared medication satisfaction ratings for differences in pain intensity level based on 
the worst NRS rating and differences in dosage forms.  In addition, we divided the sample into 
satisfied （satisfaction ratings of 5 or higher） and dissatisfied （ratings of less than 5） groups and 
identified the reasons why patients in the group with higher ratings were more satisfied.  
Statistical Analyses
　The correlations between rescue medication satisfaction and worst/average NRS ratings and 
the correlations with medication effectiveness were evaluated using Spearman’s rank correlation 
coefficient.  Additionally, the sample was divided by the patients’ worst NRS ratings into mild 
（0-3）, moderate （4-6）, and severe （7-10） groups to compare rescue medication satisfaction by 
pain intensity level using the Kruskal-Wallis test by ranks.  To compare medication satisfaction 
with difference dosage forms, the sample was divided into injection and oral/sublingual groups. 
The Mann-Whitney U test was used to identify significant differences between the two groups. 
The significance level was set at 5％ （two-tailed）.  Statistical analyses were performed using JMP 
Pro 14.0.
Ethical Considerations
　This study was conducted with the approval of the School of Medicine, Showa University 
Ethical Committee （approval no. 2852）.  All participants provided written informed consent.  It 
should be noted that when the palliative care team began intervening in patient treatment, the 
patients received a thorough explanation about opioids.
Results
Participant Characteristics
　Apart from some participant descriptive characteristics, analyses were performed on the 
responses to 100 surveys completed by the 60 study participants.  The mean age （range） was 
60.5±11.4 years （31-79 years）; 38 （63.3％） of the participants were male and 22 （36.7％） 
were female.  Forty-one （75.9％） of the participants were undergoing cancer treatment.  The 
most frequent primary cancer sites were the digestive system, followed by the lung/mediastinum. 
According to the ECOG-PS, 5 （5.0％） patients were Grade 1, 58 （58.0％） were Grade 2, and 
37 （37.0％） were Grade 3.  The median （interquartile range） for the dosage of regularly taken 
opioid analgesics in oral morphine equivalents was 45 mg/day （24-72 mg/day） （Table 1）.
Pain Control Indicators
　The medians and interquartile ranges of the worst NRS, least NRS, average NRS, and current 
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NRS ratings were 5 （4-8）, 1 （0-2）, 3 （2-4.25）, and 2 （1-4）, respectively （Table 2）.
　Rescue Medication: Satisfaction and Effectiveness 
The median （interquartile range） for rescue medication effectiveness was 8 （5-10） whereas that 
for rescue medication satisfaction was 7 （5-10）.  A strong positive correlation （r＝0.79, P＜
0.0001） was identified between rescue medication satisfaction and effectiveness.  The correlations 
for medication satisfaction with worst NRS （r＝-0.15, P＝0.16） and with average NRS （r＝-0.13, 
P＝0.13） were not statistically significant （Figure 1）.
　Comparisons of rescue medication satisfaction with pain intensity level using the worst NRS 















Cancer treatment: Y/N 41（68.3）/ 19（31.7）
Stage: Ⅱ/Ⅲ/Ⅳ  1（1.7）/ 5（8.3）/ 54（90.0）
ECOG-PS: 1/2/3＊  5（5.0）/ 58（58.0）/ 37（37.0）
Regularly prescribed opioid dosage（mg/day）＊ 
　in oral morphine equivalents
　［Median（interquartile range）］
45（24-72）
＊PS and opioid dosages are calculated for n＝100
（the number of surveys in the analysis）
ECOG-PS, Eastern Cooperative Oncology Group Performance Status
Table 2.  Pain control indicators（n＝100）
Median（interquartile range）
Pain worst（worst NRS） 5（4-8）
Pain least（least NRS） 1（0-2）
Pain average（average NRS） 3（2-4.25）
Pain current（current NRS） 2（1-4）
Rescue effect 8（5-10）
Rescue satisfaction 7（5-10）
NRS, numerical rating scale
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and mild （n＝24）, moderate （n＝45）, and severe （n＝31） pain satisfaction did not demonstrate 
significant between-group differences in pain intensity levels （Figure 2）.  The most frequent 
reasons for higher rescue medication satisfaction were that the medications were fast-acting and 
convenient （Figure 3）.  
Fig. 1.   Correlations between rescue medication satisfaction and worst NRS, 
average NRS, and rescue medication effectiveness 
NRS, numerical rating scale
Fig. 2.   Rescue medication satisfaction by pain intensity level NRS, numerical 
rating scale; Mild pain: NRS 0-3 （n＝24）, moderate pain: NRS 4-6 （n＝
45）, severe pain: NRS 7-10 （n＝31） 
Kruskal-Wallis test, P＜0.05
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　No significant between-group differences were found when rescue medication satisfaction was 
compared by grouping the responses according to injection （n＝30） and oral/sublingual （n＝70） 
dosage forms （Figure 4）.  In addition, there were no significant differences in rescue medication 
satisfaction between males and females.
Fig. 3.   Reasons for rescue medication satisfaction/dissatisfaction ratings stratified by 
the satisfied （≥5） and dissatisfied （＜5） groups （multiple responses possible）
 Notes : The patients most frequently reported higher rescue medication 
satisfaction because of fast-acting and convenient medications.
Fig. 4.  Rescue medication satisfaction by dosage form 
NRS, numerical rating scale; injection group （n＝30）, oral/sublingual group （n＝
70）; Mann-Whitney U test, P＜0.05
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Discussion
　In this study, satisfaction with rescue medication was not significantly correlated with worst and 
average NRS pain intensity ratings.  However, satisfaction was strongly correlated with rescue 
medication effectiveness.  Furthermore, there were no significant differences in the comparisons 
of rescue medication satisfaction by pain intensity level and dosage form.  These findings suggest 
that performing a pain assessment consisting of only an NRS rating after administering opioid 
analgesics may be inappropriate because some patients appeared to be satisfied with their rescue 
medication despite having high worst and average NRS pain ratings.  Instead, satisfaction with 
rescue medication was shown to better reflect medication effectiveness.  This finding suggests that 
integrating rescue medication satisfaction into daily patient pain assessments could better indicate 
whether the opioid analgesic used was effective.
　Fast-acting, convenient rescue medications were the most satisfactory forms of medication. 
Although we expected satisfaction to be higher for injections that take little time to prepare 
and are fast-acting, the results showed there was no significant difference in satisfaction between 
rescue medications in the injection and oral/sublingual forms.  This finding suggests that patient 
satisfaction depends more on medication being fast-acting than on being convenient.  Despite 
the need for convenience, hospitals frequently keep rescue medications for patients in narcotics 
cabinets to control their usage.  To increase patient satisfaction, it is necessary to devise ways 
to select a dosage form for each patient and to otherwise promote rescue medication self-
management so that they can be used immediately when necessary.  It is also important to 
select drugs according to the cause of pain and to communicate with the patient.
　Reducing or eliminating cancer-related pain is essential to improve the quality of life （QOL） 
of cancer patients.  To achieve this, pain management must be initiated quickly, and side-
effects should be comprehensively managed to ensure patient satisfaction.  Although suggestions 
and guidelines13-18） have been proposed in this regard, it remains extremely difficult to control 
cancer-related pain, which is usually experienced throughout the body and is influenced by 
multiple factors.  As a result, pain assessments must be very detailed, and assessments of patient 
satisfaction with overall pain management are generally required to be multidimensional19）.  Pain 
management assessment can also be complex because the relationship between pain severity 
and its interference with function is non-linear20）.  Furthermore, there is frequently disagreement 
between a patient’s self-reported pain and the physician’s clinical assessment of that pain21, 22）. 
Adequate, effective pain assessment is significantly affected by regional and institutional 
differences in medical provider perceptions and the extent to which opioid analgesics are used, 
among other factors23, 24）. In addition, interventions may be performed inappropriately with the 
aim of quantifying a patient’s pain, leading to frequent or repetitive questioning, which adds to 
the distress of patients undergoing cancer treatment.  As a result, complicated pain assessments 
may be difficult for providers to perform, and evaluations may sometimes rely entirely on self-
reported pain intensity levels.
　This study demonstrated that a new assessment method incorporating rescue medication 
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satisfaction and pain intensity measures could allow routine pain assessment to reflect both pain 
intensity and the effectiveness of the opioid analgesic.  This is potentially a preferable assessment 
method to self-reported pain intensity.  For example, a patient reporting intense pain and high 
satisfaction with their rescue medication may only require an increase in the dosage of the 
prescribed opioid analgesic.  For patients reporting intense pain and low satisfaction with their 
rescue medication, a review of the current treatment approach and the drug being administered 
may be required.  This method would help avoid cases of side effects due to overdosage.  For 
patients reporting dissatisfaction with their pain medication, despite reporting low pain intensity, 
non-opioid drug therapies and other methods of providing care might be necessary.
　This study has some limitations, including issues with several methodological factors and the 
risk of bias inherent to surveys.  The small sample size resulted in a potential for selection bias, 
which occurred because all the patients sampled were from a single hospital.  Thus, the results 
cannot be generalized to other populations.  Further, the cross-sectional design limits the results 
of the analysis to a specific time point.
　Recently, facilities have begun to assess the pain levels of cancer patients at admission, which 
results in quick identification of patients struggling with pain25）.  An important role of medical 
providers is to provide adequate pain management during hospitalization.  As a component of 
this role, it is useful to periodically perform a QOL assessment for whole-body pain using the 
EORTC QLQ-C30 and the BPI.  Patient satisfaction with their overall pain management fosters 
advance care planning and decision-making for patients.  Conversely, a patient’s distress and 
anxiety may increase if pain control adjustments are inadequate due to inadequate daily pain 
assessments.  In this regard, one benefit of multidisciplinary assessment and intervention is that 
the causes for patient distress and anxiety can quickly be identified.  Integrating measures of 
rescue medication satisfaction into daily pain assessments can be implemented without imposing 
a significant burden on the patient.  By doing so, the assessments can be used as a criterion 
to quickly evaluate whether to increase the dosage of the patient’s opioid analgesic and to 
avoid the risk of increasing the dosage too much.  In addition, to prevent any distress that the 
assessments may cause patients, providers could inform the patients about the importance of 
pain assessments and the benefits thereof.  Moreover, providers should perform appropriate pain 
assessments based on information shared with patients.
　This study’s findings suggest that patient satisfaction with their rescue medication can 
be routinely assessed without imposing a significant burden on the patient.  Moreover, the 
results indicated that patient satisfaction reflected the effectiveness of their rescue medication. 
Integrating rescue medication satisfaction with pain intensity measurements into a daily pain 
assessment should result in a convenient pain assessment that reflects the effectiveness of the 
patient’s rescue medication.  This assessment approach would be useful for patients taking an 
opioid analgesic because it would allow medical professionals to adjust dosages quickly and avoid 
side effects due to overdosage.
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